VivoSeq
Oncology

Hepatocellular Carcinoma Non-Resectable

2

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Hepatocellular Carcinoma Non-resectable is an early-stage landscape with 2 programs across 2 companies. The most active players are AstraZeneca, Terumo Europe N.V..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 2T

Terumo Europe N.V.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Tremelimumab

AstraZeneca

Durvalumab

AstraZeneca

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Terminated1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC): Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up (PMCF) Study
Recruiting·—·Preclinical·NCT05911633·50 enrolled
Efficacy Evaluation of 188Re-SSS Lipiodol Selective Internal Radiation Therapy of Non Operable Hepatocellular Carcinoma Patients, a Phase II Study
Terminated·CCenter Eugene Marquis·Phase 2·NCT05797870·16 enrolled
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04522544·55 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)